Tropes

www.nanotech-now.com 2015 00940.txt.txt

#Magnetic nanoparticles could be key to effective immunotherapy: New method moves promising strategy closer to clinical use Abstract: In recent years, researchers have pursued hotly immunotherapy, a promising form of treatment that relies on harnessing and training the body's own immune system to better fight cancer and infection. Now, results of a study led by Johns Hopkins investigators suggests that a device composed of a magnetic column paired with custom-made magnetic nanoparticles may hold a key to bringing immunotherapy into widespread and successful clinical use. A summary of the research, conducted in mouse and human cells, appears online July 14 in the journal ACS Nano. The Johns Hopkins team focused on training and rapidly multiplying immune system white blood cells known as T cells because of their potential as an effective weapon against cancer, according to Jonathan Schneck, M d.,Ph d.,a professor of pathology, medicine and oncology at the Johns hopkins university School of medicine's Institute for Cell Engineering.""The challenge has been to train these cells efficiently enough, and get them to divide fast enough, that we could use them as the basis of a therapy for cancer patients. We've taken a big step toward solving that problem, "he says. In a bid to simplify and streamline immune cellular therapies, Schneck, Karlo Perica, a recent M d./Ph d. graduate who worked in Schneck's lab, and others worked with artificial white blood cells. These so-called artificial antigen-presenting cells (aapcs) were pioneered by Schneck's lab and have shown promise in activating laboratory animals'immune systems to attack cancer cells. To do that Perica explains, the aapcs must interact with naive T cells already present in the body, awaiting instructions about which specific invader to target and battle. The aapcs bind to specialized receptors on the T cells'surfaces and"present"them with distinctive proteins called antigens. This process activates the T cells to ward off a virus, bacteria or tumor, as well as to make more T cells. In a previous study in mice, Schneck's team found that naive T-cells activated more effectively when multiple aapcs bound to different receptors on the cells, and then were exposed to a magnetic field. The magnets brought the aapcs and their receptors closer together priming the T cells both to battle the target cancer and divide to form more activated cells. But naive T cells are as rare in the blood as a"needle in a haystack, "Perica says. Because the ultimate goal is to harvest a patient's T cells from a blood sample, then train them and expand their numbers before putting them back into the patient, Schneck's research team looked to magnets as a potential way to separate the naive T cells from others in the blood. The team mixed blood plasma from mice and, separately humans with magnetic aapcs bearing antigens from tumors. They then ran the plasma through a magnetic column. The tumor-fighting T cells bound to aapcs and stuck to the sides of the column, while other cells washed straight through and were discarded. The magnetic field of the column activated the T cells, which were washed then off into a nourishing broth, or culture, to grow and divide. After one week, their numbers had expanded by an estimated 5, 000 to 10,000 times. Because numbers of these cells could be expanded quickly enough to be therapeutically useful the approach could open the door to individualized immunotherapy treatments that rely on a patient's own cells, says Perica. Schneck says that the use of naive T cells could make the new technique useful for more patients than another immunotherapy now being tested, which relies on other white blood cells called tumor-infiltrating lymphocytes. Those cells are trained already"to fight cancer, and researchers have shown some success isolating some of the cells from tumors, inducing them to divide, and then transferring them back into patients. But, Schneck says, not all patients are eligible for this therapy, because not all have tumor-infiltrating lymphocytes. By contrast, all people have naive T cells, so patients with cancer could potentially benefit from the new approach whether or not they have tumor-infiltrating lymphocytes.""The aapcs and magnetic column together provide the foundation for simplifying and streamlining the process of generating tumor-specific T cells for use in immunotherapy, "says Juan carlos Varela, M d.,Ph d, . a former member of Schneck's laboratory who is now an assistant professor at the Medical University of South carolina. The researchers found that the technique also worked with a mixture of aapcs bearing multiple antigens, which they say could help combat the problem of tumors mutating to evade the body's defenses.""We get multiple shots on the goal, "Schneck says. While the team initially tested the new method only on cancer antigens, Schneck says it could also potentially work for therapies against chronic infectious diseases, such as HIV. He says that if further testing goes well, clinical trials of the technique could begin within a year and a half.#####Other authors on the study are Joan Glick Bieler, Christian Schutz, Jacqueline Douglass, Andrew Skora, Yen Ling Chiu, Mathias Oelke, Kenneth Kinzler, Shibin Zhou and Bert Vogelstein, all of The Johns hopkins university. This work was supported by the National Institute of Allergy and Infectious diseases (grant numbers AI072677 and AI44129), the National Institute of General Medical sciences (grant number GM 07309), the National Cancer Institute (grant numbers CA 43460, CA 62924, CA 09243 and CA108835), the Troper Wojcicki Foundation, the Virginia and D. K. Ludwig Fund for Cancer Research, the Sol Goldman Center for Pancreatic cancer Research, the Commonwealth Foundation, and sponsored research agreements with Miltenyi Biotec and Neximmune. Under a licensing agreement between Neximmune and the Johns hopkins university, Jonathan Schneck and Mathias Oelke are entitled to a share of royalty received by the University on sales of products derived from this article. The terms of this arrangement are being managed by the Johns hopkins university in accordance with its conflict of interest policies.#####For more information, please click herecontacts: Shawna Williamswriteemail('jhmi. edu','shawna';'410-955-8236copyright Johns Hopkins Medicineissuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content. Bookmark: News and information Agilent technologies and A*STAR's Bioprocessing Technology Institute Collaborate on New Bioanalytical Methodologies July 15th, 2015for faster, larger graphene add a liquid layer July 15th, 2015nanocrystalline Thin-film Solar cells July 15th, 2015better memory with faster lasers July 14th, 2015cancer Nanospheres shield chemo drugs, safely release high doses in response to tumor secretions July 14th, 2015chemotherapeutic coatings enhance tumor-frying nanoparticles: Duke university researchers add a drug delivery mechanism to a nanoparticle therapy already proven to target, heat and destroy tumors July 13th, 2015super graphene can help treat cancer July 10th, 2015govt. -Legislation/Regulation/Funding/Policy Researchers Build a Transistor from a Molecule and A few Atoms July 14th, 2015world first: Significant development in the understanding of macroscopic quantum behavior: Researchers from Polytechnique Montral and Imperial College London demonstrate the wavelike quantum behavior of a polariton condensate on a macroscopic scale and at room temperature July 14th, 2015nanospheres shield chemo drugs, safely release high doses in response to tumor secretions July 14th, 2015better memory with faster lasers July 14th, 2015nanomedicine Agilent technologies and A*STAR's Bioprocessing Technology Institute Collaborate on New Bioanalytical Methodologies July 15th, 2015nanospheres shield chemo drugs, safely release high doses in response to tumor secretions July 14th, 2015chemotherapeutic coatings enhance tumor-frying nanoparticles: Duke university researchers add a drug delivery mechanism to a nanoparticle therapy already proven to target, heat and destroy tumors July 13th, 2015magnetic hyperthermia, an auxiliary tool in cancer treatments July 8th, 2015discoveries For faster, larger graphene add a liquid layer July 15th, 2015nanocrystalline Thin-film Solar cells July 15th, 2015better memory with faster lasers July 14th, 2015polymer mold makes perfect silicon nanostructures July 14th, 2015announcements Agilent technologies and A*STAR's Bioprocessing Technology Institute Collaborate on New Bioanalytical Methodologies July 15th, 2015for faster, larger graphene add a liquid layer July 15th, 2015nanocrystalline Thin-film Solar cells July 15th, 2015polymer mold makes perfect silicon nanostructures July 14th, 2015interviews/Book reviews/Essays/Reports/Podcasts/Journals/White papers For faster, larger graphene add a liquid layer July 15th, 2015delmic reports on a new review paper published in Nature Methods on Correlated Light & Electron microscopy from their user groups at the Universities of Delft and Groningen July 14th, 2015global Sol-Gel Nanocoatings Industry 2015: Acute Market Reports July 14th, 2015density-near-zero acoustical metamaterial made in China: Researchers create a tunable membrane'metamaterial'with near-zero density, effectively recreating the quantum tunneling effect for sound waves July 14th, 2015patents/IP/Tech Transfer/Licensing Nanospheres shield chemo drugs, safely release high doses in response to tumor secretions July 14th, 2015globalfoundries Completes Acquisition of IBM Microelectronics Business: Transaction adds differentiating technologies, world-class technologists, and intellectual property July 1st, 2015nei Announces the Issuance of Multiple Patents on Self-Healing & Superhydrophobic Coatings June 30th, 2015high-tech nanofibres could help nutrients in food hit the spot June 17th, 2015grants/Awards/Scholarships/Gifts/Contests/Honors/Records Nanocrystalline Thin-film Solar cells July 15th, 2015better memory with faster lasers July 14th, 2015simpore, Uofr, RIT Collaborate to Improve Blood Dialysis Filters July 8th, 2015miniature Technology, Large-scale Impact: Winner of the 2015 Lindros Award for translational medicine, Kjeld Janssen is pushing the boundaries of the emerging lab-on-a-chip technology July 7th, 201 0

< Back - Next >